CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
University of Parma
Parma, ItaliaPublications en collaboration avec des chercheurs de University of Parma (15)
2022
-
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339
-
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180
Computer methods and programs in biomedicine
2021
-
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
Computer Methods and Programs in Biomedicine, Vol. 208
-
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology, Vol. 96, Núm. 24, pp. E2989-E3002
2020
-
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder
Multiple Sclerosis and Related Disorders, Vol. 38
-
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Brain, Vol. 143, Núm. 9, pp. 2742-2756
2019
-
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Multiple Sclerosis and Related Disorders, Vol. 28, pp. 235-243
2018
-
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis
Multiple Sclerosis Journal, Vol. 24, Núm. 5, pp. 642-652
2017
-
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Neurology, Vol. 89, Núm. 10, pp. 1050-1059
-
Contribution of different relapse phenotypes to disability in multiple sclerosis
Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276
-
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 88, Núm. 3, pp. 196-203
-
Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response
Brain, Vol. 140, Núm. 9, pp. 2426-2443
2016
-
Defining secondary progressive multiple sclerosis
Brain, Vol. 139, Núm. 9, pp. 2395-2405
-
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, Núm. 12, pp. 1343-1349
2015
-
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
JAMA Neurology, Vol. 72, Núm. 4, pp. 405-413